We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-11.26%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$742M
AUM Growth
-$165M
Cap. Flow
-$34.2M
Cap. Flow %
-4.61%
Top 10 Hldgs %
45.48%
Holding
92
New
8
Increased
13
Reduced
17
Closed
15

Top Buys

Rank Stock Value
1
KA
Kineta, Inc. Common Stock
KA
+$16.9M
2
BPMC
Blueprint Medicines
BPMC
+$16.4M
3
TBPH icon
Theravance Biopharma
TBPH
+$9.51M
4
NVRO
NEVRO CORP.
NVRO
+$9.42M
5
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$7.84M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$23.4M
2
MGNX icon
MacroGenics
MGNX
+$21.2M
3
CLLS
Cellectis
CLLS
+$12M
4
ADXS
Advaxis Inc
ADXS
+$9.85M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 91.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KA
1
DELISTED
Kineta, Inc. Common Stock
KA
$46.6M 6.29%
27,172
+10,386
+62% +$16.9M
TBPH icon
2
Theravance Biopharma
TBPH
$873M
$45.4M 6.12%
1,425,000
+306,628
+27% +$9.51M
NVRO
3
DELISTED
NEVRO CORP.
NVRO
$43.7M 5.89%
601,044
+110,000
+22% +$9.42M
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$32.9M 4.43%
1,581,604
-107,467
-6% -$2.79M
EGRX
5
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$32.5M 4.38%
410,000
-45,995
-10% -$3.34M
NERV icon
6
Minerva Neurosciences
NERV
$191M
$31.2M 4.2%
331,555
-18,445
-5% -$1.88M
ARDX icon
7
Ardelyx
ARDX
$1.24B
$29.4M 3.97%
2,071,964
– –
ACRS icon
8
Aclaris Therapeutics
ACRS
$715M
$26.5M 3.57%
976,286
+75,000
+8% +$1.91M
HRTX icon
9
Heron Therapeutics
HRTX
$93.4M
$25.6M 3.45%
1,951,263
+180,000
+10% +$2.82M
BPMC
10
DELISTED
Blueprint Medicines
BPMC
$23.6M 3.18%
841,752
+542,882
+182% +$16.4M
LKFT
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$21.4M 2.89%
334,044
– –
CRBP icon
12
Corbus Pharmaceuticals
CRBP
$165M
$21.1M 2.85%
83,333
+16,666
+25% +$3.82M
CLSD
13
DELISTED
Clearside Biomedical
CLSD
$20.9M 2.81%
155,556
+23,009
+17% +$5.78M
MYOK
14
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$18.7M 2.52%
1,445,090
-160,700
-10% -$2.48M
PTGX icon
15
Protagonist Therapeutics
PTGX
$8.55B
$15.8M 2.13%
720,000
-80,000
-10% -$1.78M
CHRS icon
16
Coherus Oncology
CHRS
$217M
$14.6M 1.97%
519,090
-57,016
-10% -$1.6M
QTNT
17
DELISTED
Quotient Limited Ordinary Shares
QTNT
$14.2M 1.92%
73,500
+3,807
+5% +$823K
NBIX icon
18
Neurocrine Biosciences
NBIX
$18.2B
$13.9M 1.87%
359,000
-39,301
-10% -$1.78M
WVE icon
19
Wave Life Sciences
WVE
$1.12B
$13.3M 1.79%
507,907
– –
CBPO
20
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$12.1M 1.64%
112,867
– –
PTLA
21
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$12.1M 1.62%
537,000
-59,000
-10% -$1.15M
SYNH
22
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$10.5M 1.42%
200,000
– –
ARRY
23
DELISTED
Array Biopharma Inc
ARRY
$10.1M 1.36%
1,150,000
– –
FLGT icon
24
Fulgent Genetics
FLGT
$558M
$9.92M 1.34%
857,663
+57,663
+7% +$544K
OMER icon
25
Omeros
OMER
$845M
$9.67M 1.3%
975,000
-720,000
-42% -$7.35M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Cormorant Asset Management held 92 positions worth $742M, down 18% from $907M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $34.2M in Q4 2016, closing 15 positions and reducing 17 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Synergy Pharmaceuticals, Inc Common Stock worth $9.13M.

  • Cormorant Asset Management's largest Q4 2016 buy was Synergy Pharmaceuticals, Inc Common Stock: 1,500,000 shares worth $9.13M.
  • Cormorant Asset Management added most to Kineta, Inc. Common Stock in Q4 2016, an estimated $16.9M increase.
  • Cormorant Asset Management's biggest Q4 2016 reduction was Omeros, cutting an estimated $7.35M.
  • Cormorant Asset Management fully exited Clovis Oncology, Inc. in Q4 2016, selling an estimated $23.4M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $742M portfolio in Q4 2016.
  • Cormorant Asset Management opened 8 new positions and closed 15 in Q4 2016.
  • Cormorant Asset Management's portfolio value fell 18% quarter-over-quarter to $742M.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.